News

Tirzepatide and Hexarelin Stack After FDA Panel Vote: Can GHRP Blunt the GLP-1 Muscle Loss Risk?
After an FDA panel backed tirzepatide, concerns over muscle loss on GLP-1 drugs are driving interest in stacking with hexarelin. Research is thin, but the Read more...
Semaglutide Kidney Benefits: Can GLP-1 Agonists Protect Against Diabetic Nephropathy Amid Compounded Drug Warnings?
The FLOW trial shows a 24% drop in kidney risk with semaglutide, but FDA warnings on compounded forms complicate access. We examine GLP-1 renal Read more...
Restarting Semaglutide: How to Manage GI Side Effects and Boost GLP-1 Sensitivity
Restarting semaglutide after a break can trigger severe GI side effects if not managed carefully. This article explores receptor resensitization, practical Read more...
Tirzepatide vs. Retatrutide: Triple-Agonist Advances Reshape Weight Loss Expectations After Generic Ozempic Arrival
As generic semaglutide reshapes pricing, tirzepatide and the investigational retatrutide push weight loss efficacy to new levels. This analysis examines the Read more...